Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors.
Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase fusion proteins. Nevertheless, the optimal path...
| Publicado en: | Clinical Pathology pp. 1 - 14 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
9/15/2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=171988484&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 171988484 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2632010X M8A9 jtl: Clinical Pathology issn: 2632010X maglogo: Y pubinfo: dt: 9/15/2023 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 171988484 171988484 171988484 10.1177/2632010X231197080 171988484 ppf: 1 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors. aug: au: Petaccia de Macedo, Mariana Toledo Nascimento, Ellen Caroline Soares, Fernando Augusto Costa Santini, Fernando D'Almeida Costa, Felipe Werneck da Cunha, Isabela Ramella Munhoz, Rodrigo De Marchi, Pedro Carnier Jorge, Thiago William Ramos Moreira Leite, Kátia affil: Rede D'Or São Luiz, São Paulo, Brazil sug: subj: Gene Rearrangement Genes Evaluation Genetic Techniques Neoplasms Tumor Markers, Biological Mutation Genomics Consensus Practice Guidelines Immunohistochemistry Algorithms ab: Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase fusion proteins. Nevertheless, the optimal pathways and diagnostic platforms for this biomarker's screening and genomic profiling have not been defined and remain a subject of debate. A panel of national experts in molecular cancer diagnosis and treatment was convened by videoconference and suggested topics to be addressed in the literature review. The authors proposed a testing algorithm for oncogenic neurotrophic tropomyosin receptor kinase gene fusion screening and diagnosis for the Brazilian health system. This review aims to discuss the latest literature evidence and international consensus on neurotrophic tropomyosin receptor kinase gene fusion diagnosis to devise clinical guidelines for testing this biomarker. We propose an algorithm in which testing for this biomarker should be requested to diagnose advanced metastatic tumors without known driver mutations. In this strategy, Immunohistochemistry should be used as a screening test followed by confirmatory next-generation sequencing in immunohistochemistry-positive cases. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|